参附注射液对心脑血管疾病防治作用的新进展  

Progress in Role of Shenfu Injection in Prevention and Treatment of Cardio-Cerebral Vascular Diseases

作　　者：苏湾英 洪芬芳 杨树龙 

机构地区：[1]南昌大学医学部基础医学院生理教研室,南昌330006 [2]南昌大学医学部医学实验教学中心,南昌330006

出　　处：《南昌大学学报（医学版）》2018年第5期85-89,100,共6页Journal of Nanchang University：Medical Sciences

基　　金：国家自然科学基金(81660751;81660151;81260504);江西省重点研发计划项目(20161BBG70067);江西省自然科学基金(20171BAB205085);南昌大学研究生创新专项资金项目(cx2016359)

摘　　要：参附注射液(Shenfu injection,SFI)是通过现代技术提炼参附汤而成,主要含有红参和附子。本文将SFI防治心力衰竭、心肌缺血再灌注损伤、心律失常、心肌梗死、休克、冠心病、病毒性心肌炎、扩张性心肌病、心脏手术、脑血管疾病等心脑血管性疾病的相关研究机制进行综述,以了解SFI作用于心脑血管性疾病的防治机制,为临床应用提供更多的实验和理论依据。Shenfu injection(SFI)is extracted from the Shenfu Decoction by modern technology,and mainly consists of red ginseng and aconite.This paper summarizes the mechanisms of SFI action in the prevention and treatment of heart failure,myocardial ischemia reperfusion injury,arrhythmia,myocardial infarction,shock,coronary heart disease,viral myocarditis,dilated cardiomyopathy,cardiac surgery and cerebrovascular diseases,aiming to study the role of SFI in the pathogenesis of cardio-cerebral vascular diseases and to provide more experimental and theoretical evidence for clinical application.

关 键 词：参附注射液 心脑血管疾病 机制 

分 类 号：R54[医药卫生—心血管疾病] R743[医药卫生—内科学]